Business context and reporting period
The supplied filing is Trxade Group, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2014—not a filing identified as Scienture Holdings, Inc. Trxade operates a pharmaceutical business-to-business marketplace, a pharmaceutical supply business, and an IT consulting subsidiary.
Financial results and liquidity
| Metric | Three months ended Sept. 30, 2014 | Nine months ended Sept. 30, 2014 |
|---|---|---|
| Revenue | $372,690 | $904,603 |
| Gross profit (margin) | $295,537 (79.3%) | $629,474 (69.6%) |
| Operating expenses | $645,363 | $1,623,847 |
| Operating loss | $(349,826) | $(994,373) |
| Net loss | $(351,883) | $(1,574,899) |
| Loss per share | $(0.01) | $(0.05) |
For the nine-month period, cash used in operations was $699,330; investing cash flow was zero; financing provided $885,861. Cash increased $186,531 to $270,848. At September 30, current assets were $536,522, current liabilities $327,726, and working capital $208,796. The balance sheet reported no short-term debt or related-party debt; accounts payable were $218,684 and accrued liabilities $109,042. Total assets were $541,524 and shareholders’ equity was $213,798.
Material changes versus comparable periods
- Nine-month revenue rose 19.9% from $754,227, while gross profit increased to $629,474 from $62,878, principally as platform fee income—at lower cost of sales than other business lines—grew and sales mix shifted.
- Nine-month operating expenses increased to $1,623,847 from $713,869. Management cited higher staffing and payroll, professional and public-company costs, and $282,832 in stock-option expense.
- Net loss widened to $1,574,899 from $652,763, including a $576,417 loss on conversion of debt. Excluding that unusual conversion loss, the reported-period loss would still have been substantial.
- Third-quarter revenue increased to $372,690 from $323,406. Gross profit improved from a $45,266 loss to $295,537; management attributed lower cost of sales partly to a more efficient Westminster Pharmaceuticals logistics provider.
- Cash used in operations increased by $337,800 year over year, which management attributed to staffing, platform development, and professional fees.
Outlook, risks, and unusual items
Management’s stated priorities for the remainder of 2014 were continued platform development and customer growth. It estimated the next 12 months’ cost of sales and general and administrative requirements at $600,000 and $2,050,000, respectively, or $2,650,000 combined. The company said it needed significantly more cash and expected to seek further capital, with no assurance financing or revenue would be available; additional equity could dilute shareholders. It also cautioned that it may remain unprofitable. No earnings or revenue guidance was provided.
The company recorded a $576,417 loss when a $19,333 Xcellink loan was converted into 600,000 common shares, valued at $600,000. A September private placement had a total purchase price of $1.1 million; $400,000 had been received by September 30, and the remaining $700,000 was received in October, with the related securities fully issued October 16. The company also reported that disclosure controls and procedures were not effective. It reported no legal proceedings or defaults upon senior securities.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Trxade Group, Inc., although the request identifies Scienture Holdings, Inc.
- Review the drivers and sustainability of platform revenue growth and gross-margin improvement, including the effect of business mix and the logistics change.
- Assess ongoing cash needs against the company’s stated $2.65 million 12-month requirements, operating cash burn, and reliance on additional financing.
- Examine the debt-conversion valuation and the dilution from common shares, preferred-stock conversion, employee options, and warrants.
- Investigate the ineffective disclosure controls and any remediation, and reconcile the filing’s presentation of general and administrative expense with its separate stock-option expense disclosures.